In addition to decrease of inflammatory responses, treatment of amlexanox significantly decreased the production of TGFβ in KCs as well as in hepatocytes, thereby contribute to decreasing the severity of liver fibrosis. This evidence concerns the gene TGFB1 and Hepatic fibrosis.